Top 5 Biotech Startup Investors in Isle of Man in February 2025
A list of 5 angel investors and VC (Venture Capital) funds that invest in Biotech startups based in Isle of man. We rank investors based on the number of investments they made in Biotech companies from Isle of man. We update this investor list every month.Top 5 Biotech Startup Investors in Isle of Man in February 2025
Investor | Biotech Isle of Man investments |
---|---|
Greg Bailey | 1 |
Andrew Banks | 1 |
Jim Mellon | 1 |
Juvenescence | 1 |
Foresite Capital | 1 |
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Medical
- Seed, Series A, Funding Round
- United States, Isle of Man
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
- Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
- Biohaven Pharmaceutical — Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Andrew Banks - Chairman and Co-Founder @ ABRY Partners
Show more
Investment focus
- Biopharma, Biotechnology, Pharmaceutical
- Seed
- Isle of Man
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more
Investment focus
- Biotechnology, Food and Beverage, Health Care
- Series A, Seed, Funding Round
- United States, United Kingdom, Germany
Portfolio highlights
- Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Funding Round, Series A, Debt Financing
- United States, Hong Kong, Isle of Man
Portfolio highlights
- LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
- MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
- Souvien Therapeutics — Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
- Pleno — Pleno Inc. is a multi-omic instrument platform company democratizing biological target detection for clinical testing and biomedical research. The company’s proprietary Hypercoding™ technology leverages signal processing techniques from the telecommunications industry to deliver targeted biological information at unprecedented scale, precision, andperformance.
- Ikena Oncology — Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signalingpathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.
Investors by industry
Biotech
Energy
Health Care
Hardware
Gaming
Google
Artificial intelligence
Climate
Proptech
Community
FinTech
Consumer
Marketplace
Impact
EdTech
Sustainability
Venture Capital
Retail
Clean Energy
Finance
Education
Organic Food
Big Data
Web3
Food and Beverage
Financial Services
Payments
B2B
Real Estate
Publishing
Video Games
Beauty
Infrastructure
Photography
Medical
Social Network
Wellness
Music
Franchise
Mobile
Internet
Legal
Android
eSports
Construction
Sports
Enterprise Software
Social Media
Email
Art
Digital Media
Manufacturing
Local
Cannabis
Biotechnology
Recruiting
Fitness
Hospitality
Platforms
Mobile Advertising
Travel
Automotive
Wine And Spirits
Medical Device
Crowdfunding
Social
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Oil and Gas
Fashion
Theatre
Life Science
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
United Kingdom
Germany
United States
South Korea
Canada
Ireland
Australia
New Zealand
Oceania
LATAM
Africa
Asia
Japan
Saudi Arabia
China
Singapore
Spain
Vietnam
Armenia
South Africa
Middle East
Sri Lanka
Brazil
Indonesia
Europe
Qatar
Faroe Islands
Barbados
Denmark
Chile
Ecuador
Ethiopia
Estonia
Hong Kong
France
Gibraltar
Costa Rica
Greece
Finland
Croatia
Egypt
Georgia
Algeria
Ghana
Bulgaria
Bermuda
Hungary
Czech Republic
Bahrain
Belize
Belgium
Belarus
Liechtenstein
Morocco
Liberia
Lebanon
Lithuania
Kuwait
Philippines
Mexico
Norway
Jersey
Mauritius
Israel
Malaysia
Peru
Malta
Myanmar
Italy
Mali
Nicaragua
Panama
Serbia
Ukraine
Uganda
Uzbekistan
Thailand
Portugal
Senegal
Sierra Leone
Venezuela
Russian Federation
Dominican Republic
Iraq
Nigeria
Bahamas
Namibia
Azerbaijan
Iceland
United Arab Emirates
Jamaica
Honduras
Isle of Man
Bolivia
Luxembourg
Pakistan
Albania
Tajikistan
Rwanda
Bangladesh
Grenada
Romania
Jordan
Argentina
Zimbabwe
Zambia
Seychelles
Taiwan
Sweden
El Salvador
Tunisia
San Marino
Poland
Turkey
Puerto Rico
Uruguay
Slovenia
Togo
Tanzania
Kenya
Kazakhstan
Cayman Islands
Cambodia
Cameroon
Latvia
Oman
Cyprus
Austria
Switzerland
Colombia
Marshall Islands
Guatemala
Investors in Isle of Man by industry